脑膜炎球菌多糖结合疫苗的研究进展  

Advances in meningococcal polysaccharide conjugate vaccine research

作　　者：孟清霞 许项可 安文珏 张珂 MENG Qingxia;XU Xiangke;AN Wenjue;ZHANG Ke(Hualan Biological Bacterin Inc.,Xinxiang 453003,Henan Province,China;不详)

机构地区：[1]华兰生物疫苗股份有限公司,河南新乡453003 [2]华兰生物工程股份有限公司,河南新乡453003

出　　处：《中国生物制品学杂志》2024年第3期370-375,共6页Chinese Journal of Biologicals

基　　金：河南省重大科技专项(181200211800)。

摘　　要：脑膜炎球菌多糖结合疫苗基本采用化学结合方式制备,最常用的方式为酰胺缩合反应,由于多糖与蛋白以共价键形式结合,因此制备的结合疫苗稳定性较高,具有较好的技术优势,在脑膜炎球菌相关疾病预防中发挥重要作用。脑膜炎球菌多糖结合疫苗应用于2岁以内婴幼儿的免疫接种,保护效果持久。本文就脑膜炎球菌多糖结合疫苗制备的影响因素、多糖与载体蛋白的结合方式、国内外现状以及制备过程中存在的问题进行综述。Meningococcal polysaccharide conjugate vaccine is basically produced by chemical combination,and the most commonly used method is amide condensation reaction.Because of the covalent bonds between polysaccharide and protein,the prepared conjugate vaccine has high stability and good technical advantages,which plays an important role in the prevention of meningococcal related diseases.The vaccine can be applied to the immunization of young children under 2years old,and has more lasting protective effect.In this paper,the factors influencing the preparation of meningococcal polysaccharide conjugate vaccine,the binding mode of polysaccharide and carrier protein,the present situation at home and abroad and the existing problems in the preparation process were reviewed.

关 键 词：脑膜炎球菌 多糖结合疫苗 载体蛋白 

分 类 号：R392[医药卫生—免疫学]